News

AddToAny

Google+ Facebook Twitter Twitter

Cholera vaccine: single dose more effective?

New research shows that giving a stronger single dose of a live oral cholera vaccine could be an effective tool in controlling outbreaks more quickly.

Child taking oral cholera vaccine

Each year there are more than three million cases of cholera worldwide.

The standard regimen for protecting against cholera with existing non-living oral cholera vaccines includes administering two doses over a two-week period.

The latest University of Maryland School of Medicine (UMSOM) research was conducted in Mali and included 150 participants.

Researchers assessed the effectiveness (ability to stimulate vibriocidal antibody, an immune response that correlates with protection) of a single high-dose of live cholera vaccine CVD 103-HgR.

This was developed by UMSOM’s Center for Vaccine Development and licensed and manufactured by PaxVax, versus the standard two-dose killed vaccine approach.

While the two-dose inactivated vaccine approach has been used and made available for protecting against seasonal increases in cholera cases, a stronger single-dose live oral vaccine approach may be a more effective way to rapidly protect individuals in big outbreaks, the research found.

The work has been published in Clinical and Vaccine Immunology.  

bit.ly/BS_JanNews4

Picture credit | Getty

Related Articles

Science news in numbers January 2018

Science news in numbers: January 2018

A breakdown of science news this month.

"HIV vaccine design shows promise"

A novel protein-sugar vaccine candidate has stimulated an immune response against sugars that form a protective shield around HIV.

Four decades of tuberculosis

Professor Douglas Young discusses the last 40 years of tuberculosis research, as he hangs up his lab coat for the final time.

Top